AIM ImmunoTech to Announce Q2 2024 Financials on August 16, 2024, with Conference Call and Webcast

OCALA, Fla., Aug. 13, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) revealed that its management will conduct a conference call and webcast to present and review the Company’s Q2 2024 operational and financial performance. This event is scheduled for Friday, August 16, 2024, starting at 8:30 AM ET. The conference call will feature AIM’s Chief Executive Officer, Thomas K. Equels, and Scientific Officer, Christopher McAleer, PhD. 

To join the conference call, domestic participants can dial (877) 407-9219, while international callers should use (201) 689-8852, and reference the AIM ImmunoTech Conference Call. The webcast will be available on the Events page in the Investors section of AIM ImmunoTech's website, aimimmuno.com, and will be archived for 90 days post-event.

AIM ImmunoTech Inc. is a pharmaceutical company specializing in immunotherapy, concentrating on the development and research of treatments for various cancers, immune disorders, and viral infections, including COVID-19. The Company's primary product is Ampligen® (rintatolimod), an investigational drug that is a double-stranded RNA (dsRNA) and a selective Toll-Like Receptor 3 (TLR3) agonist immunomodulator. This drug is currently undergoing clinical trials and has shown broad-spectrum activity against significant global cancers, viral infections, and immune system disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!